50 closest statements
by meaning · ranked by similarity · 100 per pageMeaning search returns the 50 nearest statements, then applies your filters.
“Our mission is to be the leading player in the development and commercialization of p53-targeted cancer therapies.”In use 2022 – now·1 sighting·SEC Form 10-K, filed 2022-03-1590% match
“Our mission is to build an oncology company committed to developing first-in-class and best-in-class targeted therapies designed to improve outcomes for cancer patients.”In use 2026 – now·1 sighting·SEC Form 10-K, filed 2026-03-0373% match
“Our mission is to target cancer and transform lives through the development of innovative cancer treatments.”In use 2005 – now·1 sighting·SEC Form 10-K, filed 2005-03-1672% match
“Our mission is to become a leader in bringing innovative cancer treatments to the market and to improve patient health outcomes.”In use 2023 – now·1 sighting·SEC Form 10-K, filed 2023-03-2072% match
“Our mission is to be a leading global biopharmaceutical company focused on discovering, developing, and commercializing innovative therapies that improve the lives of patients.”In use 2026 – now·1 sighting·SEC Form 10-K, filed 2026-02-2672% match
“Our mission is to be the global leader and pioneer of this new treatment paradigm, integrating recombinant technology, gene therapy and cell therapy to address the challenges of targeting and delivering effective therapies, including to the brain for cancer and other central nervous system (“CNS”) indications.”In use 2026 – now·1 sighting·SEC Form S-1, filed 2026-08-2871% match
“Our mission is to discover, develop and commercialize small-molecule drugs to treat cancer in patients with the greatest unmet medical need – aggressive cancers where current therapies are inadequate.”In use 2016 – now·1 sighting·SEC Form 10-K, filed 2016-02-2971% match
“Our mission is to become a leading global, fully integrated biopharmaceutical company engaged in discovering, developing and commercializing both first- and best-in-class therapies to address global unmet medical needs primarily in hematological malignancies.”In use 2025 – now·1 sighting·SEC Form 424B4, filed 2025-01-2471% match
“Our mission is to develop a portfolio of innovative product candidates for the treatment of cancer.”In use 2022 – now·1 sighting·SEC Form 424B4, filed 2022-02-0771% match
“Our mission is to improve the quality of life of people suffering from cancer and to increase shareholder value by commercializing our platform technologies through in-house development, joint ventures, strategic alliances and licensing arrangements.”In use 2003 – now·1 sighting·SEC Form 10-K, filed 2003-07-2971% match
“Our mission is to leverage our unique insights into finding and binding cryptic functional pockets on currently intractable human biology-validated protein targets to discover, develop and commercialize small molecule therapies that can transform the lives of patients suffering from devastating cancers and immune disorders.”In use 2021 – now·1 sighting·SEC Form S-1, filed 2021-06-2571% match
“Our mission is to develop and commercialize first-in-class medicines based on novel targets to improve patients’ lives.”In use 2022 – now·1 sighting·SEC Form 20-F, filed 2022-03-2471% match
“Our mission is to develop and commercialize innovative antibody-based therapeutics for the treatment of solid tumors that are designed to bind depending on the physical and chemical properties of tumors and their microenvironment.”In use 2026 – now·1 sighting·SEC Form 10-K/A, filed 2026-04-2970% match
“Our mission is to build a leading oncology company that creates novel and transformative treatments for a wide range of oncology indications for which there are significant unmet medical needs.”In use 2024 – now·1 sighting·SEC Form 10-K, filed 2024-03-0770% match
“Our mission is to be the global leader in innovating, developing, and delivering tumor infiltrating lymphocyte, or TIL, cell therapies for patients with solid tumor cancers.”In use 2026 – now·1 sighting·SEC Form 10-K, filed 2026-02-2470% match
“Our mission is to benefit patients by developing and commercializing anti-cancer therapies for patients whose solid tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, with particular focus on orphan cancer indications.”In use 2024 – now·1 sighting·SEC Form 10-K, filed 2024-10-0770% match
“Our mission is to enable anyone and any company to use our integrated open-access drug discovery and development platform to discover and develop new therapeutic products to benefit patients worldwide.”In use 2015 – now·1 sighting·SEC Form 20-F, filed 2015-04-1569% match
“Our mission is to develop novel treatments for dormant cancers: targeting cancer resistance, metastasis, and relapse.”In use 2022 – now·1 sighting·SEC Form S-1/A, filed 2022-12-0869% match
“Our mission is to maximize the clinical and commercial potential of cabozantinib, and to position us for future growth through our discovery efforts and expansion of our development pipeline.”In use 2019 – now·1 sighting·SEC Form 10-K, filed 2019-02-2269% match
“Our mission is to become a global leader in the treatment of rare diseases through commercializing, developing and acquiring novel rare disease products.”In use 2021 – now·1 sighting·SEC Form 424B4, filed 2021-01-1469% match
“Our mission is to become the leading company in precision genetic medicines by discovering, developing, manufacturing, and ultimately commercializing a new class of medicines through our proprietary base editing technology, with the goal of providing life-long cures to patients suffering from serious diseases.”In use 2020 – now·1 sighting·SEC Form 424B4, filed 2020-10-0169% match
“Our mission is to develop next-generation, potentially curative cell therapies for people with cancer.”In use 2025 – now·1 sighting·SEC Form 10-K, filed 2025-03-1269% match
“Our mission is to transform cancer treatment and prevention globally by driving technological innovation and accelerating the adoption of precision oncology medicine.”In use 2020 – now·1 sighting·SEC Form 424B4, filed 2020-06-2269% match
“Our mission is to build a breakthrough oncology company creating neoantigen-based therapies that significantly improve the lives of patients.”In use 2018 – now·1 sighting·SEC Form 424B4, filed 2018-06-2869% match
“Our mission is to change the landscape of oncology drug discovery and enable the development of more effective therapies for the treatment of cancer.”In use 2025 – now·1 sighting·SEC Form S-1, filed 2025-07-1868% match
“Our mission is to improve the lives of patients by developing novel therapeutics to treat some of the most devastating types of cancer.”In use 2026 – now·1 sighting·SEC Form 10-K/A, filed 2026-06-0268% match
“Our mission is to accelerate scientific and medical breakthroughs and deliver well-tolerated medicines with greater efficacy and safety to people with the deadliest cancers.”In use 2026 – now·1 sighting·SEC Form 10-K, filed 2026-03-0568% match
“Our mission is to inspire hope for those battling cancer by expanding on the promise of targeted therapies.”In use 2023 – now·1 sighting·SEC Form 10-K, filed 2023-03-1568% match
“Our mission is to transform cancer care through the smart design and development of targeted solutions based on a deep understanding of cancer pathways and biological markers.”In use 2019 – now·1 sighting·SEC Form 10-K, filed 2019-03-0668% match
“Our mission is to develop, register and commercialize safe and effective drugs, with novel mechanisms of action, to meet the major unmet medical needs of patients on a global basis.”In use 2012 – now·1 sighting·SEC Form 10-K, filed 2012-03-1568% match
“Our mission is to create, develop, manufacture, and deliver cell and gene therapies to transform the lives of people impacted by life-threatening diseases.”In use 2024 – now·1 sighting·SEC Form 10-K, filed 2024-03-1868% match
“Our mission is to build a world-class biopharmaceutical and biotechnology company, with a leading position in key therapeutic areas.”In use 2020 – now·1 sighting·SEC Form 20-F, filed 2020-03-1268% match
“Our mission is to leverage unique insights into protein motion to transform the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development and commercialization of small molecule therapies.”In use 2026 – now·1 sighting·SEC Form 10-K, filed 2026-02-2668% match
“Our mission is to become a global leader in developing better and safer radioimmunotherapy and antibody-based oncology therapies addressing clear unmet medical needs and, as such, have a transformational impact on the lives of patients.”In use 2025 – now·1 sighting·SEC Form 10-K, filed 2025-03-0468% match
“Our mission is to be the foremost biopharma company interrogating ecDNA biology to deliver transformative therapies that improve and extend the lives of patients with previously intractable oncogene amplified cancers.”In use 2026 – now·1 sighting·SEC Form 10-K, filed 2026-03-0968% match
“Our mission is to transform the lives of cancer patients by providing innovative solutions to enable targeted delivery of therapeutic agents.”In use 2026 – now·1 sighting·SEC Form 10-K, filed 2026-03-3068% match
“Our mission is to be leaders in Israel’s biopharmaceutical industry, to identify promising drug compounds and creatively drive the development process towards commercialization.”In use 2020 – now·1 sighting·SEC Form 20-F, filed 2020-03-1268% match
“Our mission is to build the leading coagulation company by discovering, developing, and commercializing innovative therapies for the millions of patients worldwide suffering from serious bleeding and thrombotic diseases.”In use 2026 – now·1 sighting·SEC Form 424B4, filed 2026-05-0168% match
“Our mission is to transform the lives of people with severe diseases by developing and commercializing potentially curative treatments.”In use 2026 – now·1 sighting·SEC Form 10-K, filed 2026-02-2668% match
“Our mission is to develop and commercialize safe and effective therapies that extend survival and maintain the quality of life for patients with life-threatening cancers and chronic liver diseases.”In use 2004 – now·1 sighting·SEC Form 10-K, filed 2004-12-1368% match
“Our mission is to use our proprietary Alpha DaRT technology to transform the treatment of solid tumors and broaden the potential scope of local radiotherapy delivery across multiple clinical settings.”In use 2026 – now·1 sighting·SEC Form 20-F, filed 2026-03-0968% match
“Our mission is to develop new and effective immune-oncologic therapeutics.”In use 2015 – now·1 sighting·SEC Form 10-K, filed 2015-10-1468% match
“Our mission is to develop therapeutic products with the potential to address high unmet medical needs by identifying promising clinical-stage candidates and advancing their development to create products that will improve patients’ lives.”In use 2026 – now·1 sighting·SEC Form S-1, filed 2026-08-2168% match
“Our mission is to achieve a leadership position in life enhancement regenerative stem cell therapies, services, and products through a combination of first to market technologies, and innovative clinical trial strategies.”In use 2011 – now·1 sighting·SEC Form S-1, filed 2011-02-0168% match
“Our mission is to be a global leader in generics, innovative medicines and biopharmaceuticals, improving the lives of patients.”In use 2024 – now·1 sighting·SEC Form 10-K, filed 2024-02-1268% match
“Our mission is to transform cancer treatment by delivering innovative radioconjugates that maximize therapeutic efficacy while minimizing toxicity to healthy tissue by combining our deep understanding of tumor biology and translational medicine with our expertise in radiochemistry.”In use 2026 – now·1 sighting·SEC Form 10-K, filed 2026-03-3068% match
“Our mission is to discover, develop and commercialize novel and transformative therapies that improve the lives of patients with serious diseases.”In use 2024 – now·1 sighting·SEC Form 10-K, filed 2024-02-2267% match
“Our mission is to create therapies with curative potential for patients with cancer and other life-threatening immune-mediated diseases.”In use 2024 – now·1 sighting·SEC Form 10-K, filed 2024-04-1667% match
“Our mission is to become the world leader in the sustainable manufacture of KLH and use our unique, proprietary methods and intellectual property to serve the growing demand for KLH in immunotherapeutic and immunodiagnostic markets.”In use 2015 – now·1 sighting·SEC Form 10-K, filed 2015-12-1467% match
“Our mission is to discover and develop effective biologic treatments for people with life-threatening conditions and to evolve Inhibrx into a commercial-stage biopharmaceutical company with a differentiated and sustainable product portfolio by focusing on the following:.”In use 2024 – now·1 sighting·SEC Form 10-K, filed 2024-02-2867% match
Showing 1–50 of 50